Abstract

Diabetes becomes a global health burden, affecting almost one third of world population. This figure is self explanatory for its alarming growth and concern to be given for its prevention and management. It is erroneous to treat it as a disease rather it should be treated as a syndrome, because rarely it is presented in its discrete form i.e. only hyperglycemia as a clinical feature. Being a metabolic disease it is almost always accompanied with many other diseases like hypothyroidism, hypertension, fatty liver disease, obesity, dyslipidemia, etc. According to the known pathophysiology of diabetes, hyperglycemia is said to be responsible for dyslipidemia, constant high sugar level in blood produces dreaded effect at micro as well as macro- vascular level. This established pathology of the disease revolves around high glucose level in blood and make it the diagnostic parameter for diabetes. Although the cause of hyperglycemia are also well defined but there is one missing link which is totally neglected by the modern science i.e., role of liver in the pathogenesis of diabetes. Do any way hampered liver functions affect insulin production or its utilization by the cell- the question that required answer. This clinical trial is based on materializing the concept that effective bile secretion improves insulin activity. This is a pilot study carried out on 15 known patient of non insulin dependent diabetes. The study showed that 66.6% patient has diabetes associated with hypothyroidism followed by dyslipidemia (60%). The study drug shows significant (p< 0.001) reduction in both FBS and PPBS and improve the presenting symptoms effectively.

Authors and Affiliations